Less than two weeks after China’s conditional approval of Sinopharm’s COVID-19 vaccine, the chairman and a director at the state-owned drug company suddenly resigned on the same day for “personal reasons.” The unexpected news fueled public speculation and doubts over the quality of the Chinese-made vaccine.
On Jan. 12, Sinopharm Group Co. issued two consecutive announcements, stating that Li Zhiming, chairman of Sinopharm Holding Corporation, and Li Hui, director and general manager of Sinopharm Group Pharmaceutical Co., a subsidiary, have resigned due to “personal reasons.”
